GREENLAND MINES LTD Sale Leaseback Transaction, Gross Proceeds, Financing Activities
GREENLAND MINES LTD (GRML) reported Sale Leaseback Transaction, Gross Proceeds, Financing Activities of $525.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:SaleLeasebackTransactionGrossProceedsFinancingActivities · last filed 2024-04-17
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for the quarter ending 2023-12-31 was $0.00.
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for the quarter ending 2023-09-30 was $0.00.
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for the quarter ending 2023-06-30 was $0.00.
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for the quarter ending 2023-03-31 was $525.00K.
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for fiscal 2023 was $525.00K, a 0.00% change from fiscal 2022.
- GREENLAND MINES LTD sale leaseback transaction, gross proceeds, financing activities for fiscal 2022 was $525.00K.
| Period end | Sale Leaseback Transaction, Gross Proceeds, Financing Activities 3 month | Sale Leaseback Transaction, Gross Proceeds, Financing Activities 6 month | Sale Leaseback Transaction, Gross Proceeds, Financing Activities 9 month | Sale Leaseback Transaction, Gross Proceeds, Financing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $0.00 derived: sum of 2 quarters · filed 2024-04-17 | $0.00 derived: sum of 3 quarters · filed 2024-04-17 | $525.00K 10-K · filed 2024-04-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $0.00 derived: sum of 2 quarters · filed 2023-11-17 | $525.00K 10-Q · filed 2023-11-17 | $525.00K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $525.00K 10-Q · filed 2023-08-21 | $525.00K derived: sum of 3 quarters · filed 2023-10-18 | $525.00K derived: sum of 4 quarters · filed 2023-10-18 |
| 2023-03-31 | $525.00K 10-Q · filed 2023-05-24 | $525.00K derived: sum of 2 quarters · filed 2023-10-18 | $525.00K derived: sum of 3 quarters · filed 2023-10-18 | |
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-10-18 | $0.00 derived: sum of 2 quarters · filed 2023-10-18 | $525.00K 10-K/A · filed 2023-10-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $525.00K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $525.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |